Johnson & Johnson — 2011 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended January 1, 2012; it is an annual report, not a standalone fourth-quarter report. Johnson & Johnson operates more than 250 companies in roughly 60 countries, with Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments and approximately 117,900 employees.
Financial and operating highlights
- Revenue, earnings, cash flow, margins, debt, and liquidity: The filing incorporates the audited financial statements and management discussion from the shareholder annual report, but the supplied text does not provide their figures. Clear values for these measures cannot be stated from the supplied text.
- Research and development: Worldwide R&D costs were $7.5 billion in fiscal 2011, compared with $6.8 billion in 2010 and $7.0 billion in 2009.
- Product exposure: REMICADE was the company’s largest product and represented 8.4% of fiscal 2011 total revenue.
- Share repurchases: The company purchased 13,446,804 common shares during fiscal fourth-quarter periods shown in the filing; open-market purchases were made as part of a systematic plan for compensation programs.
Material changes versus prior periods
- LEVAQUIN lost U.S. market exclusivity in June 2011 and faced generic competition; sales declined 54.1% in 2011 versus 2010.
- R&D spending increased to $7.5 billion from $6.8 billion in 2010, while remaining above the 2009 level of $7.0 billion.
- The filing reports no significant worldwide sales seasonality, but says spending is generally heavier in the fourth quarter, principally for advertising and R&D.
Outlook, commentary, risks, and unusual items
- Outlook: The supplied text contains no specific financial guidance or quantified forecast. Management describes continued commitment to R&D and innovation.
- Quality and regulatory matters: A consent decree signed with the FDA in the first fiscal quarter of 2011 requires McNEIL-PPC to take enhanced remediation measures at certain facilities. The Fort Washington, Pennsylvania facility, voluntarily shut in April 2010, was to remain closed pending rebuilding, third-party certification, and FDA concurrence.
- Legal matters: The filing refers to further proceedings in incorporated notes not included in the supplied text. Separately, California regulators alleged waste-handling violations at a subsidiary facility; the company said it believed adequate defenses existed and expected resolution without significant penalties or other adverse impact.
- Business risks: The company cites intensifying regulation, product safety and efficacy requirements, pricing and health-care cost pressures, payer influence, competition, intellectual-property protection, and political or economic uncertainty in some foreign markets. Regulatory actions can include recalls, product withdrawals, seizures, and civil or criminal sanctions.
- Leadership: After fiscal year-end, the company announced Alex Gorsky would become CEO effective April 26, 2012, succeeding William C. Weldon.
- Controls: Management concluded disclosure controls and internal control over financial reporting were effective as of January 1, 2012; no material control changes were identified during the quarter.
Important facts for investors to verify
- Consult the incorporated annual-report financial statements and MD&A for fiscal 2011 revenue, earnings, margins, cash flow, debt, liquidity, and segment results, which are not stated in the supplied filing text.
- Review the incorporated legal-proceedings notes for the full scope and estimated financial effects of litigation, recalls, and government investigations.
- Track the timing and conditions for reopening the Fort Washington facility and the operational and financial effects of the FDA consent decree.
- Assess the business impact of LEVAQUIN’s generic competition and the concentration represented by REMICADE.
- Review the company’s pipeline, patent expirations, and any formal forward-looking guidance in the incorporated annual report.